Replies to post #123827 on Biotech Values

[DewDiligence]

NEOP is not necessarily a bad company; however, the stock became overvalued from heavy pumping on some iHub boards (and other venues) in much the same way that FCSC did prior to FDA approval of laViv. I would have shorted both names if I had been able to get a borrow.